Investors continue to grapple with the uncertainty hanging over the company.
News & Analysis: Mallinckrodt
Upbeat news on interest rates and asset sales lifted these stocks on an otherwise tough day for the market.
The company is reportedly considering bankruptcy to cope with its financial exposure in the opioid crisis.
Worries about opioid litigation and a recent patent lawsuit loss continue to weigh on the drugmaker.
Find out how earnings affected some of these stocks.
The bad news keeps piling up.
Investors appear to have some confidence that the companies will settle their opioid lawsuits.
Positive clinical-trial results couldn't save the embroiled biotech.
MNK earnings call for the period ending June 30, 2019.
The drugmaker's decision to suspend efforts to spin off its specialty generics business appears to be rattling investors.